IVF Medication

The procurement process, initiated by the Swansea Bay University Health Board, concerns the provision of IVF Medication, specifically for the payment of medication for self-funded patients. The buying organisation, a public authority under Welsh devolved regulations, is based in Port Talbot with involvement from the NHS Wales Shared Services Partnership. This procurement falls within the healthcare services industry and covers the completion of the contract under an open, competitive flexible procedure, fitting under the legal framework of the UKPGA 2023/54.

The award, announced on 19 June 2025, was granted to Pharmasure Ltd, with contract commencement on 20 June 2025, lasting until 7 August 2025, and valued at £275,000 GBP. The procurement stage is currently at completion, with all related processes finalised. This tender presents substantial opportunities for businesses in the healthcare supply industry, particularly those capable of providing critical pharmaceutical products or services.

Companies that specialise in healthcare services or pharmaceuticals and can meet the stringent requirements for delivery within specified timelines and adhere to competitive procurement procedures are well-suited to engage in such opportunities. Pharmasure Ltd, a large-scale supplier, was awarded this particular contract, highlighting the potential for growth and revenue in fulfilling healthcare service needs and supporting patient care through medication provision.